HomeAbout

TL;DR CNBC


Pfizer RSV vaccine maintains protection in older adults over two seasons in trial - TL;DR CNBC

Pfizer RSV vaccine maintains protection in older adults over two seasons in trial

Publishing timestamp: 2024-02-29 08:16:07


Summary

Pfizer's vaccine against respiratory syncytial virus remains effective for older adults over two seasons, with slight decline in efficacy. Advisory panel to CDC to consider whether seniors should take RSV shots annually or every other year. Moderna hopes to launch its own RSV jab. GSK's shot showed cumulative efficacy of 67.2% over two seasons. Pfizer's shot recorded about $890 million in revenue in 2023.


Sentiment: NEUTRAL

Tickers: PFEGSK-GBGSKMRNA

Keywords: biotechnologymoderna incbusinessbiotech and pharmaceuticalsgsk plcbreaking newsbusiness newspfizer inchealth care industrypharmaceuticals

Source: https://www.cnbc.com/2024/02/29/pfizer-rsv-vaccine-protects-older-adults-over-two-seasons.html


Developed by Leo Phan